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Abstract 
The HIV Rev protein mediates the transport of partially and unspliced HIV mRNA from the 
nucleus to the cytoplasm. Rev multimerizes on a secondary stem-loop structure present in the 
viral intron-containing mRNA species and recruits the cellular karyopherin CRM1 to export 
viral mRNAs from the nucleus to the cytoplasm. Previously we have identified a single-
domain intrabody (Nb190), derived from a llama heavy-chain antibody, which efficiently 
inhibits Rev multimerization and suppresses the production of infectious virus. We recently 
mapped the epitope of this nanobody and demonstrated that Rev residues K20 and Y23 are 
crucial for interaction while residues V16, H53 and L60 are important to a lesser extent. 
Here, we generated cell lines stably expressing Nb190 and assessed the capacity of these cell 
lines to suppress the replication of different HIV-1 subtypes. These cells stably expressing the 
single-domain antibody are protected from virus-induced cytopathogenic effect even in the 
context of high multiplicity of infection. In addition, the replication of different subtypes of 
group M and one strain of group O is significantly suppressed in these cell lines. Next, we 
analysed the natural variations of Rev amino acids in sequence samples from HIV-1 infected 
patients worldwide and assessed the effect of Nb190 on the most prevalent polymorphisms 
occurring at the key epitope positions (K20 and Y23) in Rev. We found that Nb190 was able to 
suppress the function of these Rev variants except for the K20N mutant, which was present in 
only 0.7% of HIV-1 sequence populations (n=4632). 
Cells stably expressing the single-domain intrabody Nb190 are protected against virus-induced 
cytopathogenic effect and display a selective survival advantage upon infection. In addition, 
Nb190 suppresses the replication of a wide range of different HIV-1 subtypes. Large-scale 
sequence analysis reveals that the Nb190 epitope positions in Rev are well conserved across 
major HIV-1 subtypes and groups. Altogether, our results indicate that Nb190 may have broad 
potential as a gene therapeutic agent against HIV-1. 
	   3 
Highlights 
- The anti-Rev single-domain intrabody Nb190 displays broad-spectrum anti-HIV activity 
against different strains of both HIV-1 groups M and O.  
- Nb190 was able to suppress the function of Rev mutants containing the most prevalent 
polymorphisms of the Nb190 epitope, except for the K20N mutant. 
-  Cells stably expressing Nb190 are protected against virus-induced cytopathogenic effect and 
display a selective survival advantage upon infection. 
 
Keywords 
HIV-1; single-domain antibody; intrabody; Rev  
  
	   4 
1. Introduction 
HIV expresses three main RNA species, fully spliced, partially spliced and unspliced RNA, 
which encode for the regulatory, structural and viral enzymatic proteins. Various viral 
proteins are thus encoded by intron-containing mRNAs, which are naturally retained in the 
nucleus and degraded by host cell mechanisms. However, the nuclear export of these intron-
containing viral mRNAs is crucial for viral replication (Pollard and Malim, 1998). To 
circumvent the nuclear retention and the degradation of these RNAs, HIV has developed a 
sophisticated mechanism. Through expression of the regulatory protein Rev, viral RNAs are 
hooked up to the cellular CRM1-mediated nuclear export pathway. Rev multimerizes on a 
secondary stem-loop structure, called Rev Responsive Element (RRE), present in all intron-
containing viral RNAs (Fischer et al., 1999; Malim et al., 1989; Sodroski et al., 1986). This 
ribonucleoprotein complex is then exported to the cytoplasm via the CRM1-mediated nuclear 
export pathway (Neville et al., 1997). In the cytoplasm these RNAs serve as templates for 
translation into viral proteins and/or as genome for packaging into newly formed viral 
particles.  
Structural analysis revealed that Rev consists of three major functional domains, (i) a nuclear 
localization signal (NLS) that also serves as RNA-binding domain and ensures binding of Rev 
to the RRE, (ii) a nuclear export signal (NES) that is essential for Rev to interact with the 
exportin CRM1 (Daelemans et al., 2005; Fischer et al., 1995; Neville et al., 1997) and (iii) 
two alpha helical multimerization domains that join together to form a head and tail 
multimerization surface, which is essential for the multimerization on the viral RNA (Jain and 
Belasco, 2001). During HIV replication, one Rev protein first binds to the RRE (stem IIB), 
facilitating dimerization via tail-tail interactions and further multimerization via both head-
head and tail-tail interactions (Daly et al., 1989; Daugherty et al., 2008; Heaphy et al., 1990; 
Malim and Cullen, 1991; Vercruysse and Daelemans, 2014; Zapp et al., 1991). Subsequently, 
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the exportin CRM1 is recruited to this ribonucleoprotein complex, which exports viral RNA 
to the cytoplasm. 
In previous research we have discovered a single-domain llama antibody (Nb190) that interacts 
with the head multimerization surface of Rev. Nb190 inhibits the multimerization of Rev and 
supresses virus production from the HIV-1 NL4.3-molecular clone (Vercruysse et al., 2010; 
Vercruysse et al., 2011). Previously published crystal structures (Daugherty et al., 2010; 
DiMattia et al., 2010) allowed us to make an interaction model of Nb190 with Rev, disclosing 
the epitope of this nanobody and demonstrated that Rev residues K20 and Y23 are crucial for 
interaction while residues V16, H53 and L60 are important to a lesser extent (Vercruysse et 
al., 2013). However, the activity of this nanobody against different HIV-1 subtypes is not 
known. 
Here, we have created cell lines that stably express Nb190 and show that these cells are 
resistant to the replication of HIV-1 subtype B. These Nb190 expressing cells display a 
selective survival advantage upon infection and were resistant to the replication of 7 different 
subtypes (subtype A, B, C, D, G and H) belonging to group M as well as a virus strain of 
group O, but not to a subtype F virus. Furthermore we analysed the natural variations of Rev 
amino acids occurring in sequence samples from HIV-1 patients worldwide and introduced 
the most prevalent polymorphisms of the key epitope residues (K20 and Y23) in wild-type 
subtype B Rev background. The binding of Nb190 to these Rev-mutants as well as its 
inhibitory activity on Rev function was assessed. Altogether, our study presents the first cell 
line stably expressing a nanobody with a broad-spectrum anti-HIV activity. Furthermore, 
Nb190 stable cells display a selective survival advantage upon infection. 
 
2. Materials and Methods 
2.1 Production of stable cell lines 
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For the generation of stable cell lines, HEK293T cells were transfected using the calcium 
phosphate method with 8 µg pCGGagPol, 2 µg of pCF-VSVG and 10 µg of pQ-puroR-
Nb190(mKO)FLAG or pQ-puroR-Nb163(mKO)FLAG (Ulm et al., 2007). Cells were grown 
overnight at 37 °C, washed and fresh medium was added. The next day, supernatant was 
harvested, spun down to remove residual cells and was added to C8166, HeLaP4 or 
U87CD4CCR5 cells with 8 µg/mL hexadimethrine bromide. After 2 days, cells were subject 
to selection by 2 µg/mL puromycin. Surviving cells were kept in culture for at least 1 week 
before use and monitored under fluorescence microscope and western blot analysis was used 
to confirm maintenance of the insert of interest. 
 
2.2 Transfections and Plasmids 
HeLa cells, maintained using standard procedures, were transfected with plasmid DNA using 
the transfection reagent Genecellin, according to the manufacturers protocol. For the co-
localisation experiment 0.1 µg of pRev-AcGFP and 0.2 µg pcDNA3.1 Nb190-mKO or Nb163-
mKO after 1 h the cells were washed with Phosphate Buffered Saline (PBS) and fresh 
medium was added. The day after, transfected HeLa cells were imaged. For the analysis of the 
stable cell lines, HeLaP4 or U87CD4CCR5 cells were transfected with pRev-AcGFP using 
Genecellin as described above. Because C8166 could not be transfected with Genecellin, co-
transduction was carried out. Protocol was analogous to the production of stable cell lines; 
except for the insert of interest that now was Rev-AcGFP. After 2 days, cells were imaged 
with a SP5 laser-scanning confocal microscope (Leica Microsystems), using an HCX plan 
apochromat x63 (numerical aperture 1.2) water immersion objective magnification. 
Monomeric Aequorea coerulescens green fluorescent protein was monitored with the argon 
laser using the 488-nm line for excitation, and emission was detected between 495 nm and 
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550 nm. Monomeric Kusabira-Orange fluorescent protein (mKO) was imaged using the 
DPSS 561-nm laser for excitation, and emission was detected between 570 nm and 670 nm. 
For the rescue experiment HeLaP4 cells, whether or not stably expressing Nb190-FLAG or 
Nb163-FLAG, were co-transfected with 0.5 µg Rev-AcGFP or mutant Rev-AcGFP and 0.5 µg 
pHIV Mrev(-) using the transfection reagent Genecellin, according the manufacturers 
protocol. After one day, supernatant was collected and virus-associated capsid protein (p24) 
was determined by an enzyme-linked immunosorbent assay (Perkin Elmer).  
Site-directed mutagenesis was performed by methylation of the parental DNA by the GpC 
methyltransferase (New England Biolabs) followed by PCR using the Platinum Taq DNA 
polymerase (Invitrogen) and primers containing the target mutations, this according to the 
manufacturers protocol.  
Cloning of the viral Bz163- and BaL- rev gene was performed as follows. Briefly, RNA was 
isolated out of infected cells with the RNeasy micro-kit (Qiagen, 74004). Reverse 
transcription of the isolated RNA to DNA was performed with the Superscript III one-step 
RT-PCR (Invitrogen) according to the manufacturers protocol. Afterwards this DNA was 
cloned into the pAcGFP-N1 vector. 
 
2.3 Infection 
C8166 and U87CD4CCR5 cells were maintained using standard procedures. In the medium 
of stable cells, 1 µg/mL puromycin was added. C8166 cells were incubated with X4-viruses 
IIIB (Subtype B), UG270 (Subtype D) and BCF06 (Group O). U87CD4CCR5 were infected 
with R5-viruses UG275 (Subtype A), ETH2220 (Subtype C), Bz163 (Subtype F), BcFDioum 
(Subtype G) and BcFKita (Subtype H) at an MOI of 0.1; 0.01; 0.001; 0.0001 or 0. Cells were 
washed 3 times with PBS and resuspended in medium 1 h or 24 h post-infection, respectively. 
Five days post-infection supernatant was collected and virus-associated core antigen (p24) 
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was determined by an enzyme-linked immunosorbent assay (Perkin Elmer) according to the 
manufactures protocol. Cell viability was determined with the MTT-method. The absorbances 
were read in an eight-channel computer-controlled photometer (Infinite M1000, Tecan), at 
two wavelengths (540 and 690 nm) as described previously (Pannecouque et al., 2008; 
Pauwels et al., 1988). For determination of selective growth advantage, C8166 co-cultures 
containing different ratio (25:75; 50:50 or 75:25) of C8166Nb190 cells with either wild-type or 
C8166Nb163 cells were infected with HIV-1 IIIB at different MOI. Cell survival was assessed 
by MTT 5 days post infection. 
For the production of NL4.3-CTE virus, the corresponding plasmid (from B. Felber and G. 
Pavlakis) was transfected in HEK293T cells. After 24 h medium was replaced and another 24 
h later supernatant was harvested. C8166 or U87CD4CCR5 cells were infected with 200, 40 
and 8 pg virus (expressed as p24 and determined by p24 ELISA). Supernatant was harvested 
after 5 days and p24 was determined as described above.  
 
2.4 Co-immunoprecipitation  
HeLa cells were transfected with pRev-AcGFP and collected after 18 h. Next to that 1x106 
HeLaP4, C8166 or U87CD4CCR5 stable cells were collected and lysed in a 0.5 % triton lysis 
buffer (50 mM NaCl, 5 mM MgCl and 50 mM Tris HCl) for 1 h on ice. The lysates were 
cleared of debris by centrifugation and supernatant of transfected cells was co-incubated with 
lysate of the stable cell line cells together with Sigma anti-FLAG M2 magnetic beads for 1 h 
at 4 °C. Beads were washed 3 times with wash buffer (50 mM NaCl, 5 mM MgCl and 50 mM 
Tris HCl). Afterwards NuPage LDS sample buffer (Life Sciences) was added together with 
DTT and samples were kept at 80 °C for 5 min in order to elute proteins from beads. Proteins 
were analysed by Western Blotting, visualising Nanobody-FLAG fusion proteins with Mouse 
anti-FLAG (F1804, Sigma-Aldrich) and Rev with rabbit anti-Rev (20-000501, Fitzgerald). 
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Secondary antibodies were Goat anti-mouse IgG-HRP (sc-2005 Santa Cruz) or Donkey pAb 
to Rabbit IgG (Abcam 9764), respectively. 
 
2.5 Fluorescence Recovery after Photo bleaching 
Fluorescence recovery after photo-bleaching studies were performed by obtaining a series of 
20 pre-bleach images of a nucleolus at 5% Acousto optical tunable filter laser setting, 
followed by a single 0.39 s bleach iteration at full laser power of a 1 µm wide circle in the 
nucleolus. Subsequent post-bleach images were acquired at 5% Acousto optical tunable filter 
with the following time scheme: 20 images every 0.39 s, 20 images every 1 s, and 15-55 
images every 10 s. Data were background-subtracted, bleach-corrected and normalized 
according to the method described in (McNally, 2008). Half times of recovery were obtained 
by fitting the recovery curves employing GraphPad Prism (GraphPad Software, Inc.). 
 
2.6 Sequence conservation analysis  
We retrieved 6346 HIV-1 Rev sequences from the HIV Los Alamos database 
(http://www.hiv.lanl.gov). Only one sequence per patient sample was included. We aligned 
sequences against the HXB2 reference and manually curated using Seaview 4.3 (Gouy et al., 
2010). Hypermutated sequences were detected by the Los Alamos hypermut tool (default 
parameters) (Rose and Korber, 2000). HIV-1 subtype classification was determined using the 
Rega (Pineda-Pena et al., 2013) and COMET subtyping tools (http://comet.retrovirology.lu/). 
Sequence quality was ensured by excluding duplicates and sequences with internal stop-
codons, hypermutations, more than 1% ambiguous nucleotides and discordant subtype 
classification. We obtained 4632 full-length HIV-1 Rev sequences that fulfilled the quality 
criteria, encompassing A1 (n = 177), B (n = 2701), C (n = 1027), D (n = 106), F1 (n = 25), F2 
(n = 8), G (n = 57), H (n = 4), J (n = 3), K (n = 2), CRF01_AE (n = 409), CRF02_AG (n = 
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91), group O (n = 6), group P (n = 2), group N (n = 9). To quantify the statistical conservation 
of amino acids at each Rev position, conservation index (CI) was calculated by averaging 
pairwise scores between all AAs using the BLOSUM62 substitution matrix (Li et al., 2013). 
The HIV-1 Rev inter- and intra-subtype diversity was calculated using the pairwise sequence 
comparison, described in our recent study (Li et al., 2013) (Table 1). 
Sequences from lab-strains were obtained from http://www.hiv.lanl.gov/cgi-­‐bin/NEWALIGN/align.cgi. 
 
3. Results 
3.1 Cell lines stably expressing Rev-binding Nb190  
We have previously shown that Nb190 inhibits virus production from HEK293T cells that 
were transfected with the NL4.3 molecular clone (subtype B) (Vercruysse et al., 2010). 
However, the effect of Nb190 on virus infection or its effect on different HIV-1 subtypes has 
not been assessed. Therefore we created C8166, U87CD4CCR5 and HeLaP4 cell lines, which 
stably express Nb190, the Nb190-mKO fusion protein or the negative control nanobody Nb163 or 
the Nb163-mKO fusion protein.  
To test the activity of the stably expressed Nb190 and its ability to interact with Rev, the 
cytoplasmic relocalization of Rev-AcGFP in the presence of Nb190 was monitored. Wild-type 
Rev is predominantly localized in the nucleoli of the cells (Kalland et al., 1994; Meyer and 
Malim, 1994). Nevertheless we have shown that interaction of Nb190 with Rev inside living 
cells causes a redistribution of both proteins to the cytoplasm (Vercruysse et al., 2010). This 
localization pattern is in line with the subcellular localization of Rev mutants that are unable 
to multimerize (Daelemans et al., 2004; Jain and Belasco, 2001; Malim and Cullen, 1991; 
Thomas et al., 1998). In HeLaP4Nb190, C8166Nb190 and U87CD4CCR5Nb190 cells, transiently 
expressed Rev-AcGFP localizes in the cytoplasm. In HeLaP4Nb190-mKO, C8166 Nb190-mKO and 
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U87CD4CCR5 Nb190-mKO cell lines expressing the Nb190-mKO fusion protein, both Rev-
AcGFP and Nb190-mKO redistribute to the cytoplasm (Fig. 1 A, B and C). These results 
demonstrate that the stably expressed intrabody Nb190 interacts with Rev in the stable cell 
lines. As a control, relocalization of Rev-AcGFP to the cytoplasm was absent in cells 
expressing the negative control Nb163 nanobody (Fig. 1 A, B and C). These results indicate 
that the fusion of mKO to the nanobody does not affect its activity. The interaction of Nb190 
with Rev in these cell lines was confirmed by co-immunoprecipitation of Rev with Nb190 (Fig. 
2).  
 
3.2 Nb190 suppresses the replication of different HIV-1 subtypes  
Next we assessed the replicative capacity of different HIV-1 subtypes in these cell lines stably 
expressing Nb190. We first assessed the replication of HIV-1 subtype B strain IIIB in these 
cells. Therefore, C8166Nb190 cells were infected with HIV-1 IIIB at different multiplicities of 
infection (MOI) and virus replication was monitored 5 days post infection by measuring the 
virus-induced cytopathogenic effect (CPE) using MTT (Pannecouque et al., 2008) (Fig. 3A) 
as well as the virus-associated p24 in the supernatant (Fig. 3B). CPE was strongly suppressed 
in Nb190 expressing cells and the replication of IIIB was strongly inhibited as compared to 
wild-type or Nb163 expressing cells. In fact, at an MOI of 0.01, virus replication was fully 
blocked in Nb190 expressing cells whereas Nb163 expressing or wild-type C8166 cells 
produced 1.6 × 105 pg/mL and 1.0 × 105 pg/mL virus-associated p24, respectively. To prove 
that the observed protection against viral replication is not due to eventual defects in cellular 
machineries caused by the stable insertion of the Nb190 in the cellular genome, replication of a 
Rev-independent virus (NL4.3-CTE) (Bray et al., 1994; Sonigo et al., 1986; Zolotukhin et al., 
1994) was assessed in these stable cell lines (Vercruysse et al., 2010). This Rev-independent 
virus relies on the Constitutive Transport Element (CTE) of the Mason-Pfizer monkey virus 
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for the nuclear export of its intron-containing mRNAs and is therefore not inhibited by Nb190 
(Bray et al., 1994; Sonigo et al., 1986; Zolotukhin et al., 1994). NL4.3-CTE virus was able to 
replicate in our stable cell lines (Fig. 4) suggesting that the stable introduction of the 
intrabody sequence as such does not affect steps in the viral replication other than the Rev 
function. Moreover, these results again confirm the strict anti-Rev activity of Nb190. 
To further determine whether Nb190 was able to suppress replication of other HIV-1 subtypes, 
infection of C8166Nb190 and U87CD4CCR5Nb190 cells was performed with respectively 
different X4- or R5-strains (Fig. 5A-B). We assessed viral replication in C8166 cells by both 
virus-induced CPE (using MTT) and virus release in the supernatant (p24 ELISA). For 
U87CD4CCR5 cells, we only assessed virus-associated p24 in the supernatants, as these cells 
are less prone to expressing CPE. Interestingly, the replication of all viruses tested was 
inhibited, except for subtype F (Bz163) (Table 2). Overall, these experiments demonstrate 
that Nb190 is able to suppress viral replication of different HIV-1 subtypes, and that cells 
stably expressing Nb190 are protected from virus-induced cytopathogenic effects. 
 
3.3 Selective survival advantage of cells stably expressing Nb190  
As Nb190 stable cell lines are resistant to CPE induction upon HIV-1 (IIIB) infection (Fig. 3A), 
we investigated whether they have a selective survival advantage compared to wild-type or 
the control Nb163 stable cell lines upon infection. Therefore C8166 co-cultures containing 
different ratio (25:75; 50:50 or 75:25) of C8166Nb190 cells with either wild-type or C8166Nb163 
cells were infected with HIV-1 IIIB at different MOI and cell survival was assessed by MTT 5 
days post infection. Results show that the higher the percentage of Nb190 expressing cells, the 
more viral particles were required to induce cell death by HIV-induced cytopathogenic effect 
(Fig. 6). Indeed, there is a clear correlation between the percentage of stable Nb190 cells and 
the amount of cell survival upon infection at a certain MOI.  
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3.4 Analysis of Rev sequence variations at the Nb190 epitope positions in large-scale HIV-1 
patient populations 
Previously we have shown that Rev residues V16, K20, Y23, H53 and L60 interact with 
Nb190. Mutation of these residues to an alanine resulted in a decreased binding affinity of 
Nb190 (Vercruysse et al., 2013). Because of the high sequence variations in HIV, we analysed 
the Rev sequences from viruses of 4632 patients worldwide and quantified the conservation 
index of the epitope residues V16, K20, Y23, H53 and L60 (Fig. 7 A and B). Despite 16.16% 
genetic diversity of HIV-1 Rev within subtype strains, 25.94% between subtypes and 52.94% 
between group strains, we found that V16, K20, Y23, and L60 are well conserved across 
major HIV-1 subtypes; however H53 was much less conserved (Fig. 7 B, C, Fig. 8 and 9). 
Notably, natural polymorphisms at residues K20 and Y23 were prevalent in less than 7% 
across HIV-1 subtypes (K20R: 5%, K20N: 0.7% or Y23H: 0.8%; Fig. 7 C). 
As we already established that K20 and Y23 are the most important epitope residues, we 
decided to introduce the most frequently observed polymorphisms at those positions (K20R, 
K20N, and Y23H mutations) into the subtype B background Rev and investigated whether 
these mutations could affect the interaction of Nb190 with Rev. We therefore co-transfected 
these Rev-AcGFP-mutants together with Nb190-mKO and monitored their subcellular 
localization as described above (Fig. 10 A and B). Wild-type Rev-AcGFP normally localizes 
to the nucleoli while in the presence of Nb190-mKO both proteins relocalize to the cytoplasm 
suggesting interaction between both proteins (Vercruysse et al., 2010). Unlike wild-type Rev-
AcGFP, the Rev-AcGFP-Y23H and Rev-AcGFP-K20N mutants already localize in the 
cytoplasm in the absence of Nb190 (Fig. 10 B). However, upon co-expression of the labelled 
Nb190-mKO fusion protein with Rev-AcGFP-Y23H, Nb190-mKO redistributed to the 
cytoplasm suggesting that Nb190 is able to interact with the Rev-Y23H mutant. Rev-AcGFP-
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K20N was unable to cause a redistribution of Nb190-mKO suggesting that the K20N mutation 
abolishes the Rev-Nb190 interaction. To our surprise, the K20R Rev mutant, which localizes to 
the nucleoli in the absence of Nb190, did not redistribute to the cytoplasm in the presence of 
Nb190, but Nb190-mKO redistributed to the nucleoli suggesting interaction of both proteins.  
To confirm the above findings, we measured the affinity of Nb190 to these Rev mutants using 
Fluorescence Recovery After Photo bleaching (FRAP). Therefore, Nb190-mKO was co-
transfected with RevM10-AcGFP containing one of the mutations. RevM10-AcGFP lacks a 
nuclear export signal (NES) and hence does not shuttle to the cytoplasm but localizes in the 
nucleoli even in the presence of Nb190. After bleaching of Nb190-mKO within a 1µm diameter 
circle in the nucleoli, its reappearance was measured in time. Recovery curves of Nb190-mKO 
bound to RevM10K20R or RevM10Y23H were similar to the one of RevM10 indicating that 
Nb190-mKO binds with comparable affinity to these proteins. However, a very fast recovery 
of Nb190-mKO was observed when bound to RevM10K20N, suggesting a very weak affinity 
(Fig. 11 A). 
To further investigate whether Nb190 can inhibit the function of these Rev mutants in virus 
replication, we co-transfected HeLaP4Nb190 cells with a Rev deficient NL4.3 molecular clone 
containing a stop codon in its rev gene together with wild-type Rev or Rev containing the 
K20R, K20N or Y23H mutations in wild-type background. Virus production from the Rev-
deficient NL4.3 clone is rescued by co-expression of Rev protein. Nb190 was able to suppress 
virus production from all Rev mutants except for RevK20N (Fig. 11 B). Remarkably, this 
mutant displayed a decreased functionality.  
 
3.4 Analysis of Bz163-resistance to Nb190  
To further investigate the resistance of Bz163 against Nb190, we introduced the amino acid 
variations of Bz163-Rev located in the Nb190-epitope (V16A and H53R) into wild-type 
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subtype B background Rev. We co-transfected HeLaP4Nb190 cells with a Rev deficient NL4.3 
molecular clone together with wild-type Rev or Rev containing the V16A, H53R or V16A-
H53R mutations. Virus production was rescued in HelaP4 and HelaP4Nb163 cells by both wild-
type as mutant Rev protein and Nb190 was able to inhibit the virus production induced by all 
single - and double mutants of Rev (Fig. 12 A). 
Because the above experiments did not elucidate the cause of resistance of strain Bz163, we 
cloned the Rev of Bz163 via reverse genetics into an expression vector and three different 
clones were tested in the same rescue experiment as described above. As a control also two 
Rev-clones of BaL were tested. The Rev proteins of both Bz163 and BaL were able to support 
virus production and Nb190 was able to inhibit this virus production (Fig. 12 B).  
 
4. Discussion  
HIV still affects millions of people worldwide and a curative therapy has not been established 
to date. The emergence of resistant viruses and side effects of long-term combination therapy 
directs science towards the development of new possible therapies (Barre-Sinoussi et al., 
2013). For example, nanobodies are small, soluble and non-immunogenic agents with high 
target binding capabilities (Muyldermans et al., 2001; Pardon et al., 2014; Siontorou, 2013). 
Several nanobodies have been under investigation in clinical phases for diverse applications 
such as the treatment of acquired thrombotic thrombocytopenic purpura and several cancers 
(Callewaert et al., 2012; Holz, 2012; Oliveira et al., 2013). Recently, we have discovered a 
nanobody (Nb190) that inhibits the multimerization of the HIV Rev protein and doing so 
suppresses the production of virus (Vercruysse et al., 2010; Vercruysse et al., 2011). It is the 
first inhibitor of its kind and it may have potential as a gene therapeutic agent against HIV. 
For long time the crystal structure of Rev remained unsolved due to the strong propensity of 
Rev to aggregate in solution. However, introduction of point mutations in the multimerization 
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domains (Daugherty et al., 2010) or the use of agents that reduce oligomerization (DiMattia et 
al., 2010; Stahl et al., 2010) allowed the elucidation of Rev’s structure. It became clear that 
the hydrophobic amino acids V16 and L60 are located at the outer surface of an alpha-helix 
and that they both play a direct role in the multimerization of Rev by forming key stabilizing 
interactions. The polar residue Y23 participates in interactions within the monomer Rev and 
bridges interactions with the second Rev molecule in the dimer-formation. The 3D-structure 
of the Rev dimer further provided detailed information on the position of the amino acids at 
the surface of this multimerization domain. This formed the basis for a thorough structural 
analysis of the binding interaction to elucidate the forces driving dimerization and higher-
order multimerization of the Rev protein (Venken et al., 2012). This information combined 
with the results of our previous experiments allowed us to make an interaction model of Nb190 
binding at the head multimerization domain of Rev disclosing the amino acids that play an 
important role in the interaction between Rev and Nb190, being V16, K20, Y23, H53 and L60 
(Vercruysse et al., 2013).  
In the current study we investigated the broad-spectrum anti-HIV activity of Nb190 by means 
of cell lines that stably express this nanobody. We could not detect any cytotoxicity or 
negative effect on cell proliferation over months of cell culturing in these cell lines stably 
expressing the nanobody. Furthermore in contrast to wild-type C8166 cells, cells stably 
expressing Nb190 were resistant for viral replication and survived infection with virus. In 
Nb190 expressing cell lines replication of HIV-1 subtype A, B, C, D, G, H and group O is 
severely impaired. One exception was subtype F (Bz163) that is insensitive to Nb190; 
nevertheless this subtype accounts for only 0.45% of the global number of HIV-1 infections 
worldwide (Abecasis et al., 2013; Hemelaar et al., 2011). Sequence analysis of subtype F 
strain Bz163 revealed that this virus contains two amino acid variations (V16A and H53R) in 
the epitope of the Rev protein (Table 3). Analysis of 4632 patient samples (Figure 7 and 8) 
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revealed that only 0.8% of the Rev sequences contain an alanine at position 16 (subtype B and 
C) whereas 77% (subtype B, C, G, F and H) of the patient samples contain an arginine instead 
of a histidine residue at position 53. Double mutants (V16A-H53R) occurred in less than 
0.8% of the HIV-1 patient population. Similar dual variations (V16I and H53D) were found 
in UG275 (subtype A) and BcF06 (group O) viruses. Although Nb190 was able to suppress 
replication of these viruses, they were less sensitive than the IIIB strain (Fig. 5 and Table 2). 
Variations in just one amino acid residue at positions V16 or H53 did not strongly affect the 
inhibition by Nb190 (see BaL, BcFDioum or BcFKita, Table 2 and 3). These findings suggest 
that the combination of at least two mutations in these epitope hot spot positions of Rev 
severely decreases or abolishes the inhibitory activity of the nanobody. Further in depth 
investigation of the resistance of Bz163 towards Nb190 led to an interesting observation. We 
first introduced V16A, H53R and V16A-H53R double mutations into the subtype B Rev 
background and investigated whether these mutations could account for the observed 
resistance profile. Rescue experiments revealed that Nb190 could still inhibit the Rev function 
from these subtype B mutants (Fig. 12 A). Therefore, in a next step we subcloned the full 
Bz163 Rev sequence via reverse genetics into an expression vector and three different clones 
were tested in the same rescue experiment (Fig. 12 B). In this setup the nanobody was still 
able to inhibit the function of Bz163 Rev. Therefore, resistance of Bz163 to Nb190 could not 
be explained by site directed mutagenesis or reverse genetics and future research will further 
have to explore the mechanism of the observed resistance. 
To further predict the inhibitory potential of Nb190 against HIV-1 viruses prevailing amongst 
patients, we examined the prevalence of the important epitope residues using a large-scale 
dataset with Rev sequences sampled from 4632 HIV-1 patients (Fig. 7C and Fig. 8). The key 
epitope residues K20 and Y23 (Vercruysse et al., 2013) are well conserved across the HIV-1 
population. For K20 only 5 % of the viruses contain R and 0.7% contain N at this position, 
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whereas only 0.8% of the viruses varied at position 23 (Y to H). To investigate the effect of 
these specific Rev variations on the activity of Nb190, we introduced mutations (K20R, K20N 
or Y23H) into a Rev subtype B background. The K20R and Y23H mutations did not affect 
the binding with Nb190 while K20N dramatically decreased the affinity of Nb190. These 
observations may be explained by the fact that a lysine to asparagine mutation (K20N) causes 
a change from positively charged to polar propensities. Mutation of lysine to arginine (K20R) 
on the other hand preserves the long side chain and charge for interactions with the Nb190 
residues, T33, Y105 and D107 (Vercruysse et al., 2013). Also, mutation of a tyrosine to 
histidine (Y23H), does not introduce dramatic change of residue size and histidine can still 
engage in a π-π interaction with the F100 residue of Nb190 (Vercruysse et al., 2013).  
Altogether, a broad analysis of patient samples combined with a variety of experimental data 
demonstrates that Nb190 displays a broad-spectrum anti-HIV-1 activity. Although nanobodies 
have good potential as drug molecules we do believe that, because of the intracellular 
localisation of the target, intravenous application of Nb190 as anti-HIV agent in the clinic is 
not likely unless future developments in the nanobody research field would allow its entry 
into cells. As such the nanobody will not enter the cell, and additional modifications (such as 
membrane permeable peptides) might be required to make a nanobody that permeates the cell 
membrane. In contrast, Nb190 may be further developed for gene therapeutic strategies 
involving the transduction of T-cells to generate immune systems resistant to HIV infection 
(Anderson and Akkina, 2008; Zhen and Kitchen, 2014). Therefore in future studies we will 
study it in Primary Blood Monocytic cells and initiate in viral resistance studies. Secondly 
Nb190 can stand as a model for drug discovery efforts in future studies. 
 
5. Conclusion 
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In conclusion, we show that a single-domain llama antibody that inhibits the multimerization 
of the HIV Rev protein can be stably expressed in different cell lines. Interestingly, these cells 
are protected from virus-induced cytopathogenic effect even at high multiplicity of infection. 
In addition this single-domain antibody displays broad-spectrum anti-HIV-1 activity. 
Sequence analysis revealed that the epitope residues are largely conserved across different 
major HIV-1 subtype strains. We conclude that this nanobody may have potential for further 
development as gene therapeutic agent. 
Figures 
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Fig. 1 Co-expression of Rev and Nb190 results in a relocalization of both Nb190 and Rev 
(A) U87CD4CCR5 or (B) HeLaP4 cells stably expressing the negative control Nb163(mKO) 
or the active Nb190(mKO) were transfected with Rev-AcGFP. GFP (green) and mKO (red) 
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were visualized using confocal fluorescence microscopy. The third column shows differential 
interference contrast (DIC).  
(C) C8166 cells stably expressing the negative control Nb163(mKO) or the active Nb190(mKO) 
were transduced with a vector expressing Rev-AcGFP. GFP (green) and mKO (red) were 
visualized using confocal fluorescence microscopy. The third column shows differential 
interference contrast (DIC).  
 
Fig. 2 Nb190 interacts with Rev in Nb190 expressing stable cell lines as demonstrated by 
co-immunoprecipitation  
Lysate of HeLa cells transfected with Rev-AcGFP was mixed with lysate of wild-type 
(C8166, HeLaP4, U78CD4R5) cells or cells stably expressing Nb190(mKO) or the negative 
control Nb163(mKO). Nanobodies (bait, IP) with the bound Rev (prey, co-IP) were pulled-
down out of the mixture using coated magnetic beads. Presence of nanobody (IP) and/or Rev 
(co-IP) in the pull-down was visualized by western blotting. 
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Fig. 3 Stably expressing Nb190 cell lines are resistant to HIV-1 IIIB replication and are 
protected from CPE 
C8166 stable cell lines were infected with HIV-1 (IIIB) at different multiplicities of infection 
(MOI). Five days post infection, cell viability was assessed using MTT (A) and virus 
replication was assessed by quantification of the virus-associated p24 in the supernatant of 
infected cell cultures (B). Average of 3 independent experiments with standard deviations 
(SD) are shown. 
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Fig. 4 Stable expression of Nb190 does not affect the replication of Rev-independent virus 
U87CD4CCR5 and C8166 stable cells were infected with NL4.3-CTE virus and p24 was 
measured after 5 days. X-axis is showing the input amount of p24 (pg/mL). Average of 3 
independent experiments with SD are shown. 
	   24 
 
 
 
Fig. 5 Nb190 displays broad-spectrum anti-HIV activity  
(A) Nb190 or Nb163 expressing C8166 cells or wild-type C8166 cells were infected with HIV-1 
strains UG275 or BcF06 at different multiplicities of infection (MOI). One hour post infection 
cells were washed and further cultured at 37°C. Virus induced CPE using MTT and p24 in the 
supernatant were determined 5 days post infection. For BcF06, only MTT-method was used. 
Average of 3 independent experiments with SD are shown. 
(B) Nb190 or Nb163 expressing U87CD4CCR5 cells or wild-type U87CD4CCR5 cells were 
infected with R5-viruses BaL, ETH2220, UG270 Bz163, BcFDioum, and BcFKita. The 
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amount of virus-associated p24 in the supernatant was determined by ELISA 5 days post 
infection. Average of 3 independent experiments with SD are shown. 
 
Fig. 6 C8166 Nb190 cells display a selective growth advantage upon HIV-1 infection 
Co-cultures of different amounts of (A) wild-type C8166 cells with C8166Nb163 stable cell 
lines or (B) C8166Nb163 with C8166Nb190 stable cell lines or (C) wild-type C8166 cells with 
C8166Nb190 stable cell lines were infected with HIV-1 IIIB virus at different MOI. Five days 
post infection cell viability was assessed with the MTT-method. Average of 3 independent 
experiments with SD are shown. 
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Fig. 7 Sequence analysis of epitope residues in Rev among 4632 viral strains  
(A) Protein interaction positions are mapped onto Rev protein structure.  
(B) Surface spectrum colors indicate the conservatory index (CI) for each position, from the 
most conserved (blue CI = 0) to the least conserved positions (pink CI ≥ 0.15)(Li et al., 
2013). Visualization software: PyMOL V1.5 (http://www.pymol.org/).  
(C) Prevalence of natural variations at 116 Rev positions of HIV-1 group M (subtypes: A1, B, 
C, D, G and CRF01_AE, CRF02_AG). HXB2 indices are shown on top of the colored bars. 
Identified nanobody interaction positions are marked with red stars. Consensus subtype B 
amino acid for each position is shown directly under the bar, and is highlighted in green when 
the consensus amino acid differed in one or more subtypes. Natural polymorphisms are 
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shown below the consensus subtype B amino acids; proportions (%) are colored blue for 
proportion ≥ 5%; orange otherwise. 
 
Fig. 8 Consensus sequences of different subtypes and groups  
This figure shows the distribution of HIV-1 Rev natural polymorphisms within each 
individual subtype. HXB2 indices at each individual protein are shown in the first column, 
followed by HXB2 indices in the full-length Rev. Protein interaction positions are marked 
with red stars. The remaining columns list the consensus amino acid for each subtype 
followed by its natural variation(s) and the corresponding proportion(s) in blue (prevalence 
above 5%) and orange (prevalence at or below 5%). The amount of strains evaluated for each 
subtype are as follows: A (n = 177), B (n = 2701), C (n = 1027), D (n = 106), F (n = 33), G (n 
= 57), H (n=4), group O (n=6). 
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Fig. 9 Surface representation of Rev amino acid conservation in different HIV-1 
subtypes  
Surface spectrum colors indicate the CI at each position, from the most conserved (blue CI = 
0) to the least conserved positions (pink CI ≥ 0.15). Visualization software: PyMOL V1.5 
(http://www.pymol.org/). 
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Fig. 10 Redistribution of Rev-AcGFP mutants in the presence of Nb190-mKO 
(A) HeLa cells were co-transfected with Rev-AcGFP together with active Nb190-mKO or the 
negative control Nb163-mKO. GFP (green) and mKO (red) were visualized by confocal 
fluorescence microscopy. The third column shows differential interference contrast (DIC) 
images.  
	   30 
(B) HeLa cells were transfected with different Rev mutants fused to AcGFP. GFP (green) was 
visualized using confocal fluorescence microscopy. The second column shows differential 
interference contrast (DIC) images. 
 
Fig. 11 Affinity of Nb190 for K20 or Y23 Rev mutants and effect of Nb190 on virus 
production in presence of these mutants 
(A) Fluorescence Recovery after Photobleaching (FRAP) of Nb190 interaction with the 
RevM10 mutant. Relative affinity of the Rev mutants was determined by FRAP of Nb190-
mKO when bound to RevM10GFP. Values are averages ± SEM (n ≥ 9)  
(B) Wild-type HeLa P4 cells or HeLa P4 stably expressing Nb190 or Nb163 were co-transfected 
with Rev-deficient NL4.3 and mutants of Rev. Virus production from the Rev-deficient 
NL4.3 clone is rescued by co-expression of Rev protein. Twenty-four hours post transfection 
virus production was determined by monitoring the virus-associated p24 in the supernatant by 
ELISA. Average of 3 independent experiments with standard deviations (SD) are shown. 
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Fig. 12 Nb190 inhibits the function of Rev containing the V16A, H53R or double V16A-
H53R mutations and of full-length Bz163 Rev  
A. Wild-type HeLa P4 cells or HeLa P4 cells stably expressing Nb190 or Nb163 were co-
transfected with Rev-deficient NL4.3 and mutants of Rev containing the Bz163-epitope 
mutations V16A, H53R, or V16AH53R. Twenty-four hours post transfection virus production 
was determined by monitoring the virus-associated p24 in the supernatant by ELISA. Average 
of 3 independent experiments with standard deviations (SD) are shown. 
B. The Rev sequence of both subtype F Bz163 and subtype B BaL were cloned into an 
expression vector by means of reverse genetics. Three independent clones for Bz163 Rev and 
2 independent clones from subtype B BaL Rev were selected. Wild-type HeLa P4 cells or 
HeLa P4 cells stably expressing Nb190 or Nb163 were co-transfected with Rev-deficient NL4.3 
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and either clones of Rev-Bz163 or Rev-BaL. Twenty-four hours post transfection virus 
production was determined by monitoring the virus-associated p24 in the supernatant by 
ELISA. As control reference NL4.3 Rev was used. Average of 3 independent experiments 
with standard deviations (SD) are shown. 
 
Tables 
Table 1. The inter- and intra-subtype diversity of HIV-1 Rev amino acid sequences (%) 
 
  HIV-1 group M Group 
N 
Group 
O 
Group 
P 
 
 B A1 C D F1 G H J K 01_AE 02_AG 
Intra-diversity B 0.18 0.17 0.16 0.15 0.15 0.17 0.20 0.07 0.23 0.13 0.15 0.12 0.22 0.12 
Inter-diversity A1 
 
0.27 0.32 0.22 0.26 0.26 0.28 0.29 0.31 0.28 0.26 0.39 0.57 0.58 
 
C 
  
0.26 0.25 0.25 0.22 0.25 0.22 0.3 0.22 0.21 0.38 0.55 0.56 
 
D 
   
0.29 0.26 0.26 0.31 0.26 0.32 0.28 0.26 0.4 0.55 0.56 
 
F1 
    
0.23 0.24 0.27 0.27 0.29 0.27 0.25 0.4 0.56 0.58 
 
G 
     
0.23 0.26 0.23 0.26 0.24 0.23 0.38 0.55 0.54 
 
H 
      
0.25 0.25 0.28 0.21 0.21 0.36 0.56 0.57 
 
J 
       
0.26 0.32 0.26 0.25 0.37 0.55 0.58 
 
K 
        
0.27 0.26 0.24 0.4 0.56 0.57 
 
01_AE 
         
0.31 0.28 0.41 0.57 0.57 
 
02_AG 
          
0.2 0.36 0.56 0.58 
 
N 
           
0.36 0.55 0.58 
 
O 
            
0.55 0.56 
 
P 
             
0.55 
 
Using the amino acid sequences collected from HIV-1 subtype A1, B, C, D, F1, G, H, J, K, 
CRF01_AE, CRF02_AG, group O, N and P (see methods), we performed pairwise sequence 
comparison to measure the genetic diversity within each subtype, CRF or group dataset (so-
called: intra-diversity), as well as the genetic diversity between two different subtype, CRF or 
group datasets (so-called inter-diversity). 	  	  
Table 2. Fold inhibition of different subtypes  
Subtype     A    B                 B     C    D    F      G      H    O 
Virus UG275    IIIB BaL ETH2220 UG270 Bz163 BcFDioum BcFKita BcF06 
Fold 
inhibition   >10  >100 000 >10 000  >100 >10 000     ≤1    >100 > 10 000   >10 
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Relative inhibitory activity of Nb190 as compared to the effect of Nb163 for different subtypes 
calculated as the ratio of the maximum p24 values in Nb190-expressing cells on p24 values in 
Nb163-expressing cells at the same MOI measured at day 5 post infection. For BcF06 the fold 
inhibition was determined by calculating the ratio of 50% cell culture infective dose  
(CCID50) determined by titration using the MTT method at day 5 post infection. 
 
Table 3. Amino acid sequence of the Rev epitope residues in different HIV-1 subtypes 
  
V16 K20 Y23 H53 L60 
Subtype A UG275 I K Y D L 
Subtype B IIIB V K Y H L 
 
BaL V K Y R L 
Subtype C ETH2220 V K Y H L 
Subtype D UG270 V K Y H L 
Subtype F Bz 163 A K Y R L 
Subtype G BcFDioum V K Y D L 
Subtype H BcF Kita V K Y D L 
Subtype O BcF06 I K Y D L 
 
Sequences of different strains of different clades at positions V16, K20, Y23, H53 and L60 
are shown. When compared to wild-type NL4.3, residue substitutions occurring in the 
different strains are indicated in bold; amino acids depicted in black are the same as in NL4.3.  
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